Mesoblast lining up partners for stem cell trials – The Australian

The Australian Financial ReviewMesoblast lining up partners for stem cell trialsThe AustralianMesoblast's 30-patient trial found an injection of the company's MPC-300-IV product, an allogeneic mesenchymal precursor cell, was safe and improved organ function. The Melbourne-based company presented the results in poster form at the annual
http://blog.zandcell.com/mesoblast-lining-up-partners-for-stem-cell-trials-the-australian-2/